PUMPING IRONY: New Hope, Selectively Dispensed
The controversy surrounding the FDA’s approval of the first new Alzheimer’s drug in nearly two decades will do little to temper demand by desperate patients and their caregivers. It may also exacerbate racial disparities among those vying for the treatment.